Logo image of ATXS

ASTRIA THERAPEUTICS INC (ATXS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ATXS - US04635X1028 - Common Stock

12.85 USD
-0.07 (-0.54%)
Last: 12/16/2025, 12:17:06 PM
Fundamental Rating

3

Taking everything into account, ATXS scores 3 out of 10 in our fundamental rating. ATXS was compared to 529 industry peers in the Biotechnology industry. ATXS has a great financial health rating, but its profitability evaluates not so good. ATXS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ATXS has reported negative net income.
In the past year ATXS has reported a negative cash flow from operations.
ATXS had negative earnings in each of the past 5 years.
ATXS had a negative operating cash flow in each of the past 5 years.
ATXS Yearly Net Income VS EBIT VS OCF VS FCFATXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

ATXS's Return On Assets of -45.62% is in line compared to the rest of the industry. ATXS outperforms 53.31% of its industry peers.
The Return On Equity of ATXS (-53.17%) is better than 64.27% of its industry peers.
Industry RankSector Rank
ROA -45.62%
ROE -53.17%
ROIC N/A
ROA(3y)-26.21%
ROA(5y)-65.84%
ROE(3y)-27.65%
ROE(5y)-70.79%
ROIC(3y)N/A
ROIC(5y)N/A
ATXS Yearly ROA, ROE, ROICATXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATXS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATXS Yearly Profit, Operating, Gross MarginsATXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, ATXS has more shares outstanding
The number of shares outstanding for ATXS has been increased compared to 5 years ago.
ATXS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ATXS Yearly Shares OutstandingATXS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ATXS Yearly Total Debt VS Total AssetsATXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ATXS has an Altman-Z score of 6.84. This indicates that ATXS is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ATXS (6.84) is better than 76.56% of its industry peers.
There is no outstanding debt for ATXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.84
ROIC/WACCN/A
WACCN/A
ATXS Yearly LT Debt VS Equity VS FCFATXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 10.78 indicates that ATXS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 10.78, ATXS belongs to the top of the industry, outperforming 84.50% of the companies in the same industry.
A Quick Ratio of 10.78 indicates that ATXS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 10.78, ATXS belongs to the top of the industry, outperforming 84.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.78
Quick Ratio 10.78
ATXS Yearly Current Assets VS Current LiabilitesATXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.44% over the past year.
EPS 1Y (TTM)12.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ATXS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.30% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-53.66%
EPS Next 2Y-26.06%
EPS Next 3Y-11.95%
EPS Next 5Y7.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATXS Yearly Revenue VS EstimatesATXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
ATXS Yearly EPS VS EstimatesATXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ATXS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATXS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATXS Price Earnings VS Forward Price EarningsATXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATXS Per share dataATXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

ATXS's earnings are expected to decrease with -11.95% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.06%
EPS Next 3Y-11.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ATXS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ASTRIA THERAPEUTICS INC

NASDAQ:ATXS (12/16/2025, 12:17:06 PM)

12.85

-0.07 (-0.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-09 2026-03-09/amc
Inst Owners77.65%
Inst Owner Change-0.1%
Ins Owners0.48%
Ins Owner Change0%
Market Cap733.48M
Revenue(TTM)706.00K
Net Income(TTM)-124.03M
Analysts71.43
Price Target21.62 (68.25%)
Short Float %9.56%
Short Ratio1.99
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.74%
Min EPS beat(2)-38.11%
Max EPS beat(2)4.64%
EPS beat(4)2
Avg EPS beat(4)1.09%
Min EPS beat(4)-38.11%
Max EPS beat(4)56.57%
EPS beat(8)3
Avg EPS beat(8)-2.91%
EPS beat(12)6
Avg EPS beat(12)-0.93%
EPS beat(16)8
Avg EPS beat(16)-98.75%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-17.94%
PT rev (3m)-29.04%
EPS NQ rev (1m)-0.31%
EPS NQ rev (3m)-0.31%
EPS NY rev (1m)-3.64%
EPS NY rev (3m)-1.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-37.3%
Revenue NY rev (3m)-37.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1038.92
P/FCF N/A
P/OCF N/A
P/B 3.14
P/tB 3.14
EV/EBITDA N/A
EPS(TTM)-1.9
EYN/A
EPS(NY)-2.27
Fwd EYN/A
FCF(TTM)-2.11
FCFYN/A
OCF(TTM)-2.1
OCFYN/A
SpS0.01
BVpS4.09
TBVpS4.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45.62%
ROE -53.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.21%
ROA(5y)-65.84%
ROE(3y)-27.65%
ROE(5y)-70.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 83.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.78
Quick Ratio 10.78
Altman-Z 6.84
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.95%
EPS Next Y-53.66%
EPS Next 2Y-26.06%
EPS Next 3Y-11.95%
EPS Next 5Y7.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.43%
EBIT Next 3Y-20.11%
EBIT Next 5Y-16.07%
FCF growth 1Y-146.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-145%
OCF growth 3YN/A
OCF growth 5YN/A

ASTRIA THERAPEUTICS INC / ATXS FAQ

Can you provide the ChartMill fundamental rating for ASTRIA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ATXS.


What is the valuation status of ASTRIA THERAPEUTICS INC (ATXS) stock?

ChartMill assigns a valuation rating of 0 / 10 to ASTRIA THERAPEUTICS INC (ATXS). This can be considered as Overvalued.


What is the profitability of ATXS stock?

ASTRIA THERAPEUTICS INC (ATXS) has a profitability rating of 1 / 10.


Can you provide the financial health for ATXS stock?

The financial health rating of ASTRIA THERAPEUTICS INC (ATXS) is 8 / 10.


What is the expected EPS growth for ASTRIA THERAPEUTICS INC (ATXS) stock?

The Earnings per Share (EPS) of ASTRIA THERAPEUTICS INC (ATXS) is expected to decline by -53.66% in the next year.